17,124 Shares in Amgen Inc. $AMGN Acquired by Fideuram Asset Management Ireland dac

Key Points

• Fideuram Asset Management Ireland dac opened a new position in Amgen during the fourth quarter, buying 17,124 shares worth about $5.4 million.
• Amgen’s latest quarterly results beat Wall Street estimates, with EPS of $5.15 versus $4.77 expected and revenue of $8.62 billion, up 5.8% year over year.
• The company also declared a quarterly dividend of $2.52 per share, equal to $10.08 annually and a roughly 3.0% yield.

Fideuram Asset Management Ireland dac acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,124 shares of the medical research company's stock, valued at approximately $5,395,000.

Several other hedge funds have also recently bought and sold shares of AMGN. Capital World Investors raised its holdings in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the period. Geode Capital Management LLC raised its holdings in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company's stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the period. Vanguard Group Inc. raised its holdings in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. National Bank of Canada FI raised its holdings in Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock worth $346,076,000 after buying an additional 863,216 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock worth $383,254,000 after buying an additional 567,400 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

NASDAQ AMGN opened at $336.48 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The company has a market capitalization of $181.60 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 3.37 and a beta of 0.44. The firm's 50 day moving average is $342.83 and its 200-day moving average is $345.39.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen's dividend payout ratio (DPR) is 70.15%.

Analyst Ratings Changes

Several analysts have commented on AMGN shares. Citigroup raised their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Morgan Stanley set a $332.00 target price on shares of Amgen in a report on Friday, May 1st. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They set a "hold" rating and a $366.00 target price on the stock. TD Cowen restated a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of "Hold" and a consensus price target of $355.19.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.